The backend infrastructure built by compound pharmacies to serve telehealth giants like Hims and Ro is now mature. This creates an opportunity for new brands to quickly launch and ship prescription products, effectively using these pharmacies as a platform for regulated health and wellness DTC.

By offering deep discounts exclusively through select telehealth platforms, drugmakers create a powerful sales channel that may incentivize providers to preferentially prescribe their products. This arrangement raises ethical concerns that financial incentives could override independent medical judgment, potentially compromising patient care.

The true breakthrough of the GLP-1 weight-loss market wasn't just consumer ads or cash payments. It was the creation of new distribution channels like direct-to-patient platforms (e.g., Lilly Direct) and the strategic use of telehealth, which created frictionless access to branded prescriptions.

For out-of-pocket drugs like oral Wegovy, Novo Nordisk leverages telehealth platforms for distribution. This GTM strategy achieves rapid patient uptake, contrasting with slower, traditional models that rely on educating and detailing primary care physicians, reaching 300,000 UK patients in weeks.

The emergence of low-cost, compounded versions of GLP-1 drugs from telehealth companies like Hims is creating significant pricing pressure on market leaders Novo Nordisk and Eli Lilly. This dynamic has pushed the pharma giants toward direct-to-consumer models with lower prices to compete.

Direct-to-consumer telehealth companies like Hims achieve rapid growth via a vertically integrated model of marketing, medical groups, and pharmacies. This structure allows them to generate revenue from selling medicines, a more scalable business than relying on fees from the practice of medicine alone.

Telehealth platforms built on selling generic drugs face margin compression from price wars and high customer acquisition costs. Partnering to offer branded, in-demand medications provides a competitive advantage, creating a "gravitational pull" that attracts patients and builds a more defensible business model.

Novo Nordisk and Eli Lilly, after criticizing telehealth companies for unsafe compounded drugs, now partner with and promote platforms like LifeMD, which are accused of questionable prescribing practices. This suggests a potential hypocrisy driven by the need for broad market access for their branded GLP-1s.

Companies like "Prescriberee" operate with a business model targeting life sciences firms as clients. Their goal is not holistic care but efficiently converting interested patients into prescriptions, with one executive citing a 90% conversion rate for eligible patients.